Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Am J Clin Oncol ; 47(1): 30-39, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38148710

ABSTRACT

OBJECTIVE: To evaluate the survival benefit of combining primary tumor resection (PTR) and chemotherapy in patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM). METHODS: We obtained data from the surveillance, epidemiology, and end results database for patients with UCR-MAC-LM from 2010 to 2017. Clinicopathological characteristics were analyzed using the χ2 test. Propensity score matching was performed to balance baseline characteristics. Kaplan-Meier analysis and log-rank tests were used to estimate and compare survival outcomes. Univariate and multivariate Cox regression analyses were conducted to identify the prognostic factors. RESULTS: A total of 10,178 patients with unresectable colorectal adenocarcinoma with liver metastasis were included, of whom 6.01% (n=612) had UCR-MAC-LM. The UCR-MAC-LM group had a higher proportion of female patients, a greater number of elderly patients, an increased incidence of right colon localization, larger tumor size, and higher T and N staging than the unresectable colorectal non-mucinous adenocarcinoma with liver metastasis group (P<0.05). Multivariate analysis identified several independent prognostic factors (P<0.05). Patients with unresectable colorectal adenocarcinoma with liver metastasis who underwent PTR+C had superior survival rates compared with those who received PTR/C alone or no treatment (cancer-specific survival, P<0.05; overall survival, P<0.05). Subgroup analysis revealed that 17 of 22 groups of patients with UCR-MAC-LM who received PTR+C had significantly prolonged long-term survival compared with those who received PTR/C alone. CONCLUSIONS: This surveillance, epidemiology, and end results-based study indicates that PTR+C may offer a survival advantage for a specific subgroup of patients with UCR-MAC-LM compared with PTR/C alone. Nonetheless, additional clinical trials are necessary to validate these findings.


Subject(s)
Adenocarcinoma, Mucinous , Adenocarcinoma , Colorectal Neoplasms , Liver Neoplasms , Humans , Female , Aged , Colorectal Neoplasms/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Adenocarcinoma, Mucinous/drug therapy , Adenocarcinoma, Mucinous/surgery , Kaplan-Meier Estimate , Prognosis , Retrospective Studies
2.
Cancer Med ; 9(14): 5258-5271, 2020 07.
Article in English | MEDLINE | ID: mdl-32476259

ABSTRACT

Non-coding RNA 886 (nc886/VTRNA2-1) is a Pol III transcript and an atypical imprinted gene. Its exact function as a negative regulator of protein kinase R establishes its connection with innate immunity. Studies have shown that nc886 silencing is closely associated with prostate cancer progression. Previous work has constructed a cell model of stable nc886 overexpression ("mimic" or "nc886+ ") in PC-3M-1E8 cell lines (1E8), which are highly bone-metastatic human prostate cancer cells with low expression of nc886, and cells expressing the mimic were validated to have lower invasive and metastatic abilities than cells expressing the scramble transcript in vitro and in vivo. In this study, we directly injected mimic or scramble cells into the left ventricle of C57BL/C mice, an immunocompetent animal model, to elucidate the immune mechanisms of tumor-host interactions. Interestingly, we found that tumor cells induced the inflammation of many important organs due to xenogeneic antigen rejection; this inflammation was ultimately repaired by tissue fibrosis after 28 days, except for in the spleen. The reason is that mimic cells, as heterogeneous antigens, are mostly directly recognized by macrophages or T cells in blood, and few mimic cells enter the spleen compared with scramble cells. The induction of splenic macrophage polarization to M2 macrophages by scramble cells is a critical factor in maintaining chronic splenic inflammation. In addition, we recognize that nc886 broadly decreases the expression of some human leukocyte antigen molecules and antigen transporters. This evidence reveals the interesting role of nc886 in regulating tumor cell antigens.


Subject(s)
RNA, Untranslated/genetics , Animals , Cell Line, Tumor , Disease Models, Animal , Male , Mice , Mice, Inbred C57BL
3.
Obes Res Clin Pract ; 7(3): e206-10, 2013.
Article in English | MEDLINE | ID: mdl-23697589

ABSTRACT

OBJECTIVE: The purpose of the metabolic syndrome (MetS) concept was to early identify subjects having risk for developing cardiovascular diseases and diabetes, which of both are involved in low grade inflammation and obesity. We wish to explore the role of adipokines and inflammatory marker in young type 2 diabetics (YDM) with MetS. METHODS: Forty-eight YDM patients were divided to 2 and 3 groups according to the presence of the MetS (MetS+ and MetS-), and the numbers of MetS component (MetS-2 to MetS-4 with 1-2, 3, and 4-5 components) respectively. Plasma adipokines (tumor necrosis factor-α; TNF-α and adiponectin) and C-reactive protein (CRP) were measured and compared among groups. RESULTS: Blood pressure (BP), body mass index (BMI), and plasma triglyceride (TG) levels were higher in the group with MetS+ than that of MetS-. Except for diastolic BP, BMI, waist, and plasma TG levels, which were generally lower in the MetS-2 group, the rest demographic characteristics were not different among these three groups. Finally, the plasma adiponectin, CRP and TNF-αlevels were not different between both groups with or without MetS; and also among these three groups regardless the component numbers they had. CONCLUSION: YDM with MetS might have non-significant lower adiponectin and higher CRP levels compared to subjects without MetS. It needs prospective study with larger scale to explicit the role of cytokines and inflammatory markers in YDM with MetS.


Subject(s)
Adipokines/blood , Cardiovascular Diseases/blood , Diabetes Mellitus, Type 2/blood , Diabetic Angiopathies/blood , Inflammation/blood , Metabolic Syndrome/blood , Biomarkers/blood , Body Mass Index , C-Reactive Protein/metabolism , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Cross-Sectional Studies , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Angiopathies/epidemiology , Diabetic Angiopathies/physiopathology , Female , Humans , Inflammation/epidemiology , Inflammation/physiopathology , Inflammation Mediators/blood , Insulin Resistance , Male , Metabolic Syndrome/epidemiology , Metabolic Syndrome/physiopathology , Pilot Projects , Risk Factors , Taiwan/epidemiology , Triglycerides , Young Adult
4.
Clin Nephrol ; 80(6): 474-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-22579271

ABSTRACT

Ertapenem, a novel carbapenem with long-acting antimicrobial activity, is predominantly eliminated by the kidneys. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in patients with advanced renal failure not yet on dialysis has not been reported. Two patients with Stage 5 chronic kidney disease (CKD) developed progressive hallucinations, asterixis, myoclonic jerks, and cognitive impairment after receiving the recommended dose reduction for CKD of ertapenem (500 mg/d) for 4 days (Case 1: acute cholecystitis) and 5 days (Case 2: arteriovenous fistula infection). Exhaustive diagnostic workups were non-revealing. Plasma ertapenem level measured 24 h after the last dose in Patient 2 was 53.7 mg/l, much higher than the therapeutic MIC90 (2 mg/l). Despite the cessation of ertapenem and initiation of high-flux hemodialysis, their neurologic manifestations lasted for 2 weeks. The structural and pharmacokinetic characteristics of ertapenem such as its high lipophilicity, central nervous penetration, and volume of distribution contributed to sustained neurotoxicity even with significant reduction in plasma ertapenem levels by high-flux hemodialysis. Although ertapenem 500 mg/d has been recommended in patients with glomerular filtration rate less than 30 ml/min/1.73 m2, our 2 cases highlight that this dosage might be excessive for patients with Stage 5 CKD, especially those not yet on dialysis.


Subject(s)
Anti-Bacterial Agents/adverse effects , Neurotoxicity Syndromes/etiology , Renal Insufficiency, Chronic/metabolism , beta-Lactams/adverse effects , Acute Disease , Aged , Ertapenem , Female , Humans , Renal Insufficiency, Chronic/drug therapy , beta-Lactams/pharmacokinetics
5.
Kaohsiung J Med Sci ; 28(4): 212-5, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22453069

ABSTRACT

This study investigated the clinical pathologic character of malignant gastrointestinal stromal tumors (MGIST), their treatment with surgery, and evaluated the efficacy of imatinib postoperation. A total of 68 MGIST patients were enrolled. Of these, 27 patients underwent imatinib auxiliary therapy (treatment group) and 41 underwent imatinib therapy (control group). The therapeutic effects on the two groups were compared using χ(2) test analysis after follow-up of two years. The expressions of CD117, CD34, S100, Vimentin, and alpha smooth-muscle actin (SMA) were detected by immunohistochemistry methods. Of the 68 cases, 28 showed potential MGIST, whereas 40 had MGIST. Haemorrhagia or necrosis, abundant cell, manifest heteromorphism, and caryocinesia were observed in varying degrees. The positive rates of CD117, CD34, Vimentin, S100, and SMA were 89.7% (61/62), 88.2% (60/62), 73.5% (50/62), 41.1% (28/62) and 25.0% (17/62), respectively. The recurrence rate in the treatment group was significantly lower than that in the control group (p < 0.01). We concluded that CD117 and CD34 may be the most valuable markers in the diagnosis of MGIST, and the diagnosis of MGIST depends on the pathology. Surgery is a far better approach in the treatment of such patients, and imatinib is the more efficient target drug in preventing recurrence and metastasis.


Subject(s)
Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/surgery , Adult , Aged , Female , Gastrectomy , Gastrointestinal Stromal Tumors/classification , Gastrointestinal Stromal Tumors/drug therapy , Humans , Immunohistochemistry , Male , Middle Aged
6.
Gen Hosp Psychiatry ; 34(2): 210.e1-4, 2012.
Article in English | MEDLINE | ID: mdl-21943867

ABSTRACT

We present the case of a previously healthy man in whom acute psychosis masked the major symptomatology of thyroid storm. This patient highlights the importance of taking into consideration a life-threatening condition, thyroid storm, in the differential diagnosis of acute psychosis, even in the absence of a history of thyrotoxicosis.


Subject(s)
Psychiatric Department, Hospital , Psychotic Disorders/etiology , Thyroid Crisis/diagnosis , Diagnosis, Differential , Humans , Inpatients , Male , Thyroid Crisis/complications , Thyroid Crisis/physiopathology
7.
Genet Test Mol Biomarkers ; 16(2): 142-5, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21895484

ABSTRACT

Genome-wide association studies provide information implicating 5,10-methenyltetrahydrofolate synthetase (MTHFS) as a candidate gene for renal disease. In the Atherosclerosis Risk in Communities study, the intronic single-nucleotide polymorphism rs6495446 in the gene MTHFS confirmed the association between this gene and renal disease among Caucasian participants. We replicated this genetic association in a Taiwanese population with diabetic nephropathy (DN). A total of 358 Taiwanese patients with type 2 diabetes (T2D) were recruited. The case group comprised 180 T2D patients with DN, and the control group comprised the remaining patients without DN. rs6495446 in MTHFS had no significant effect on the risk of DN in Taiwanese patients with T2D. Multivariate logistic regression analysis demonstrated that being male, the duration of diabetes, plasma triglyceride level, and glycemic control were factors that predicted the development of DN.


Subject(s)
Asian People/genetics , Carbon-Nitrogen Ligases/genetics , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/genetics , Polymorphism, Single Nucleotide/genetics , Aged , Case-Control Studies , Diabetes Mellitus, Type 2/genetics , Female , Genetic Predisposition to Disease , Genome-Wide Association Study , Genotype , Humans , Introns/genetics , Male , Middle Aged , Taiwan
8.
Genet Test Mol Biomarkers ; 15(10): 685-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21689001

ABSTRACT

BACKGROUND: Diabetic nephropathy (DN) is the most common cause of end-stage renal disease in Taiwan. Recent studies have demonstrated that the gene for apolipoprotein E (APOE) is associated with end-stage renal disease in African Americans. In this study, we aimed to test the hypothesis that common single-nucleotide polymorphisms in the APOE gene might contribute to the development of DN in a Taiwanese population with type 2 diabetes (T2D). METHODS: We enrolled 180 patients with T2D found to have DN and 178 age- and sex-matched patients with T2D but without DN. The single-nucleotide polymorphisms rs7412 and rs429358 and common allele variants in the APOE gene were evaluated to test any association with DN. Multivariate logistic regression testing was used to determine factors associated with the risk of DN. RESULTS: The DN group had lower high-density lipoprotein cholesterol levels and longer duration of diabetes, higher systolic and diastolic blood pressure, and higher blood urea nitrogen, creatinine, and triglyceride concentrations than the group with T2D but without DN. Analyses showed no significant effects of APOE rs7412 and APOE rs429358 on the frequencies of the allele and genotype between subjects with T2D with and without DN. There were also no significant effects of APOE2 or E4 carriers on the development of DN, but multivariate logistic regression testing revealed that the duration of diabetes and triglyceride and hemoglobin A1c concentrations had independent effects on the development of DN. CONCLUSION: The APOE gene might not contribute to the risk of DN in Taiwanese patients with T2D.


Subject(s)
Apolipoproteins E/genetics , Diabetic Nephropathies/genetics , Polymorphism, Single Nucleotide , Adult , Aged , Asian People/genetics , Case-Control Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/ethnology , Diabetes Mellitus, Type 2/genetics , Diabetic Nephropathies/ethnology , Female , Gene Frequency , Genetic Association Studies , Genetics, Population , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide/physiology , Taiwan
9.
Int J Psychiatry Med ; 42(3): 211-26, 2011.
Article in English | MEDLINE | ID: mdl-22439294

ABSTRACT

OBJECTIVES: We aimed to investigate levels of brain-derived neurotrophic factor (BDNF), adiponectin, and proinflammatory cytokines in various subtypes of depression in a cohort of young men. METHODS: Sixty-two men 18-30 years of age were recruited for the study. Forty-two were newly diagnosed with depression according to DSM-IV criteria and were divided into three subtypes: reactive depression (N = 13), major depression (N = 18), and bipolar depression (N = 10). Controls included 21 young men without significant clinical morbidity. Serum levels of BDNF, adiponectin, high sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) were measured. RESULTS: Serum BDNF was significantly lower and TNF-alpha significantly higher than controls for all subtypes of depression. No statistically significant differences between subtypes were found for BDNF, adiponectin, hsCRP, TNF-alpha, or IL-6. Although established diagnosis of depression and level of TNF-alpha were found to independently affect BDNF level in depressed subjects, they executed inverse effects. No associations were found between BDNF and adiponectin, hsCRP, TNF-alpha, or IL-6 in any depressed subject, showing that decreased BDNF in depression is influenced by multiple factors and complex mechanisms, including environmental and genetic concerns. No influence of age on BDNF level was found in any depressive subtype. CONCLUSIONS: Our results lend support to the cytokine and neurotrophic hypotheses of depression by demonstrating significantly lower levels of BDNF in all subtypes of depression. The mechanism underlying this phenomenon is uncertain and assumed to be multifactorial. Development of novel antidepressant treatments will require a multidisciplinary approach.


Subject(s)
Adiponectin/blood , Bipolar Disorder/blood , Brain-Derived Neurotrophic Factor/blood , C-Reactive Protein/metabolism , Depressive Disorder/blood , Interleukin-6/blood , Tumor Necrosis Factor-alpha/blood , Adolescent , Adult , Biomarkers/blood , Humans , Inflammation/blood , Male
10.
Zhonghua Gan Zang Bing Za Zhi ; 17(6): 422-5, 2009 Jun.
Article in Chinese | MEDLINE | ID: mdl-19567019

ABSTRACT

OBJECTIVE: To investigate the effect of osteopontin (OPN) on the invasion and metastasis of human hapatocellular carcinoma (HCC). METHODS: HCC cell lines (HCC-LM3) were transfected with the chemically synthesized small interfering RNA (siRNA). Real-time PCR and Western blot were used to quantify the mRNA and OPN protein levels. The malignant phenotypes including cellular growth, colony formation and invasion capability of the HCC cells were analyzed. RESULTS: The OPN mRNA and proteins levels were decreased by 75% and 80% in OPN siRNA treated cells. Colony formation and migratory capability were reduced in OPN siRNA treated cells (P < 0.05). CONCLUSION: The specific siRNA is able to reduce the OPN expression at both the mRNA and protein levels and significantly inhibits the invasiveness of HCC cells.


Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Osteopontin/genetics , RNA, Small Interfering/genetics , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Cell Proliferation , Gene Expression Regulation, Neoplastic , Genetic Vectors , Humans , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , Neoplasm Invasiveness/prevention & control , Neoplasm Metastasis/prevention & control , Osteopontin/antagonists & inhibitors , Osteopontin/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transfection
11.
Int J Urol ; 15(6): 540-2, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18489644

ABSTRACT

Adrenocortical carcinoma can recur frequently after successful surgery but no adequate markers can detect this recurrence. Here, we present a recurrence of adrenocortical carcinoma with a high renin expression, after successful surgery, where hypertension has developed again. Tumor recurrence was observed via (18)F-fluorodeoxyglucose positron emission tomography and coregistered computed tomography. Based on our findings, follow-up blood pressure assessment may effectively predict the recurrence of adrenocortical carcinoma.


Subject(s)
Adrenal Cortex Neoplasms/complications , Adrenal Cortex Neoplasms/metabolism , Adrenocortical Carcinoma/complications , Adrenocortical Carcinoma/metabolism , Hypertension/etiology , Neoplasm Recurrence, Local/complications , Neoplasm Recurrence, Local/metabolism , Renin/biosynthesis , Female , Humans , Hypertension/diagnosis , Middle Aged
12.
Zhonghua Wei Chang Wai Ke Za Zhi ; 9(5): 409-11, 2006 Sep.
Article in Chinese | MEDLINE | ID: mdl-17043962

ABSTRACT

OBJECTIVE: To investigate the clinicopathological characteristics, and treatment of malignant gastrointestinal stromal tumors (MGIST). METHODS: Immunohistochemistry was used to detect CD117, CD34, S100, vimentin and SMA expressions. The postoperative curative effect was compared between the patients with or without imatinib treatment. RESULTS: Radical resection was performed in 60 cases. Twenty-two tumors with a mean diameter of 5.3 cm were potentially malignant, and 38 tumor with a mean diameter of 9.2 cm were malignant. Microscopical examination revealed haemorrhagia or necrosis, abundant tumor cells, heteromorphism and caryocinesia of the tumors. 54 Cases were CD117 positive, 53 cases CD34 positive, 48 cases vimentin positive, 27 cases S100 positiveì16 cases SMA positive. The two-year recurrence rate was 80.5% in the patients without postoperative imatinib treatment, significantly higher than 21.1% in the patients with postoperative imatinib treatment(P< 0.05). CONCLUSIONS: CD117 and CD34 markers are most valuable diagnostic indexes of MGIST, but its final diagnosis depends on pathology. Postoperative imatinib treatment is most effective to control recurrence and metastasis.


Subject(s)
Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/therapy , Adult , Aged , Antigens, CD34/metabolism , Antineoplastic Agents/therapeutic use , Benzamides , Female , Humans , Imatinib Mesylate , Male , Middle Aged , Piperazines/therapeutic use , Proto-Oncogene Proteins c-kit/metabolism , Pyrimidines/therapeutic use , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...